Immunic, Inc. Reports Q2 2026 Results; Ex‑CEO Separation, New Director

What Happened

• Immunic, Inc. (IMUX) filed an 8‑K (Aug 11, 2026) furnishing a press release with its financial results for the quarter ended June 30, 2026, and a corporate update. The filing also discloses board and leadership changes: Elena Ridloff was appointed to the Board effective August 6, 2026, and former CEO Daniel Vitt’s employment with the company terminated under a Separation Agreement dated August 7, 2026. Dr. Vitt had previously stepped down as CEO effective June 1, 2026 but continued in a scientific role until the Separation Date.

Key Details

• New director: Elena Ridloff (age 46), CFO of Sionna Therapeutics since Sept 2021, appointed Aug 6, 2026; received an inaugural option grant for 50,740 shares vesting monthly over three years (exercise price = Nasdaq close on Aug 6, 2026) and will receive standard non‑employee director cash compensation.
• Separation terms for Dr. Daniel Vitt (Separation Agreement dated Aug 7, 2026): he will serve as Chair of the Scientific Advisory Board and as a consultant to Immunic AG for up to 12 months for up to 15 hours/month at a €15,000 monthly retainer.
• Severance and related payments (subject to execution/non‑revocation of a release): aggregate bonus of $276,375 (75% of 2026 target) payable lump sum; first 12 salary installments aggregating $670,000 payable in a lump sum after the release effective date, with additional installments thereafter; reimbursement for German health insurance up to €1,500/month for 18 months; up to $20,000 for legal fees.
• Equity and other rights: 100% of Dr. Vitt’s outstanding equity awards vested as of the Separation Date; he has three years from the Separation Date to exercise vested awards.

Why It Matters

• Investors should note two material points in this filing: (1) the company released Q2 2026 results and a corporate update (see the company press release for the financial details), and (2) leadership changes include the formal separation of the former CEO with defined cash and equity impacts and the addition of an experienced life‑sciences finance executive to the board. The Separation Agreement creates near‑term cash obligations (lump sum and installment payments, bonus, and benefits reimbursements) and vested equity that could affect dilution if exercised. The new director brings financial and industry experience that may influence corporate governance and investor communications going forward.